UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.66 Billion Holdings in Intuitive Surgical, Inc. $ISRG

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,938,463 shares of the medical equipment provider’s stock after selling 227,708 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.83% of Intuitive Surgical worth $1,664,228,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Draper Asset Management LLC boosted its stake in Intuitive Surgical by 41.9% in the fourth quarter. Draper Asset Management LLC now owns 5,029 shares of the medical equipment provider’s stock valued at $2,848,000 after buying an additional 1,485 shares in the last quarter. Deutsche Bank AG boosted its stake in Intuitive Surgical by 9.6% in the fourth quarter. Deutsche Bank AG now owns 1,522,191 shares of the medical equipment provider’s stock valued at $862,108,000 after buying an additional 132,966 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its stake in Intuitive Surgical by 29.3% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 71,077 shares of the medical equipment provider’s stock valued at $40,255,000 after buying an additional 16,119 shares in the last quarter. Procyon Advisors LLC boosted its stake in Intuitive Surgical by 787.8% in the fourth quarter. Procyon Advisors LLC now owns 4,794 shares of the medical equipment provider’s stock valued at $2,715,000 after buying an additional 4,254 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Intuitive Surgical by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock valued at $15,026,776,000 after buying an additional 263,828 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Amy L. Ladd sold 500 shares of the stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $473.46, for a total value of $236,730.00. Following the completion of the transaction, the director directly owned 239 shares in the company, valued at approximately $113,156.94. This trade represents a 67.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $420.55, for a total value of $2,365,593.75. Following the transaction, the senior vice president owned 6,463 shares of the company’s stock, valued at $2,718,014.65. This trade represents a 46.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 7,169 shares of company stock worth $3,059,135. 0.60% of the stock is currently owned by insiders.

Intuitive Surgical Trading Down 0.4%

Intuitive Surgical stock opened at $411.06 on Friday. The company has a market capitalization of $145.58 billion, a PE ratio of 49.83, a P/E/G ratio of 3.30 and a beta of 1.46. Intuitive Surgical, Inc. has a 12 month low of $396.68 and a 12 month high of $603.88. The stock has a 50-day moving average price of $442.88 and a two-hundred day moving average price of $496.19.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, beating the consensus estimate of $2.08 by $0.42. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.62 billion. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The business’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period last year, the company earned $1.81 earnings per share. As a group, analysts predict that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ISRG shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Intuitive Surgical in a research note on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft reduced their price objective on Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating on the stock in a research note on Tuesday, June 2nd. Robert W. Baird raised their price objective on Intuitive Surgical from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. JPMorgan Chase & Co. dropped their target price on Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. Finally, BTIG Research reiterated a “buy” rating and issued a $574.00 target price on shares of Intuitive Surgical in a research report on Wednesday, April 22nd. Nineteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $571.28.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analyst coverage remains broadly constructive, with brokerage sentiment still at a “Moderate Buy” and recent EPS estimate increases signaling confidence in Intuitive Surgical’s growth outlook.
• Positive Sentiment: Recent commentary highlights that the company’s scale, cost discipline, and adoption of the da Vinci 5 platform could help protect margins even if tariffs and input costs remain a concern.
• Neutral Sentiment: Investor attention has increased around ISRG, which can support trading activity, but this appears more like watchlist interest than a fresh business catalyst.
• Neutral Sentiment: BofA trimmed its price target slightly to $515 from $520, which still implies upside but signals a bit less optimism than before. Article: BofA adjusts price target on Intuitive Surgical to $515 from $520
• Neutral Sentiment: Two executives sold shares under pre-arranged 10b5-1 plans, including EVP Gary Loeb and EVP Mark Brosius. The sales were relatively small and routine, so they are unlikely to be a major fundamental concern.
• Negative Sentiment: One recent research note was notably bearish, with Deutsche Bank cutting its target to $366 and maintaining a sell rating, reinforcing concerns that valuation may still be too rich despite the company’s strong operating performance.
• Negative Sentiment: Seeking Alpha published a view calling Intuitive Surgical an “excellent business, unattractive stock,” reflecting ongoing investor caution around the valuation. Article: Intuitive Surgical: Excellent Business, Unattractive Stock

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.